JP2021520777A5 - - Google Patents

Info

Publication number
JP2021520777A5
JP2021520777A5 JP2020551506A JP2020551506A JP2021520777A5 JP 2021520777 A5 JP2021520777 A5 JP 2021520777A5 JP 2020551506 A JP2020551506 A JP 2020551506A JP 2020551506 A JP2020551506 A JP 2020551506A JP 2021520777 A5 JP2021520777 A5 JP 2021520777A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Application number
JP2020551506A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019186276A5 (https=
JP2021520777A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000358 external-priority patent/WO2019186276A2/en
Publication of JP2021520777A publication Critical patent/JP2021520777A/ja
Publication of JPWO2019186276A5 publication Critical patent/JPWO2019186276A5/ja
Publication of JP2021520777A5 publication Critical patent/JP2021520777A5/ja
Pending legal-status Critical Current

Links

JP2020551506A 2018-03-28 2019-03-27 アルツハイマー病を検出および処置するための抗体に基づく方法 Pending JP2021520777A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862649208P 2018-03-28 2018-03-28
US62/649,208 2018-03-28
US201862664662P 2018-04-30 2018-04-30
US62/664,662 2018-04-30
US201862703299P 2018-07-25 2018-07-25
US62/703,299 2018-07-25
PCT/IB2019/000358 WO2019186276A2 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2021520777A JP2021520777A (ja) 2021-08-26
JPWO2019186276A5 JPWO2019186276A5 (https=) 2022-04-04
JP2021520777A5 true JP2021520777A5 (https=) 2022-04-04

Family

ID=66999856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551506A Pending JP2021520777A (ja) 2018-03-28 2019-03-27 アルツハイマー病を検出および処置するための抗体に基づく方法

Country Status (12)

Country Link
EP (1) EP3774887A2 (https=)
JP (1) JP2021520777A (https=)
KR (1) KR20200144551A (https=)
CN (1) CN112236452A (https=)
AU (1) AU2019244481A1 (https=)
BR (1) BR112020018868A2 (https=)
CA (1) CA3095443A1 (https=)
IL (1) IL277577A (https=)
MX (1) MX2020009991A (https=)
RU (1) RU2020135052A (https=)
SG (1) SG11202008098TA (https=)
WO (1) WO2019186276A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antibodies recognizing tau
EP4028040A2 (en) 2019-09-09 2022-07-20 Axon Neuroscience SE Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
EP4263599A1 (en) * 2020-12-16 2023-10-25 Voyager Therapeutics, Inc. Tau binding compounds
WO2022176959A1 (en) * 2021-02-19 2022-08-25 Eisai R&D Management Co., Ltd. Anti-pt217 tau antibody
CN117460954A (zh) * 2021-03-31 2024-01-26 华盛顿大学 作为tau蛋白病的生物标志物的CSF磷酸化tau和β-淀粉样蛋白概况
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
CN114778856B (zh) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 磷酸化tau蛋白检测试剂盒
CN115078736B (zh) * 2022-06-24 2025-03-25 佛山市观迪医疗器械有限公司 一种用于阿尔茨海默症的均相免疫检测试剂盒
CN119836437A (zh) * 2022-08-19 2025-04-15 舒泰神(加州)生物科技有限公司 特异性识别程序性细胞死亡1配体1的抗体及其用途
CN117624351B (zh) * 2023-11-24 2024-07-05 无锡傲锐东源生物科技有限公司 一种抗人磷酸化tau181兔单克隆抗体及其应用
CN120118184A (zh) * 2023-12-08 2025-06-10 深圳湾实验室 靶向Tau的特异性结合蛋白及其应用
WO2025160022A1 (en) * 2024-01-26 2025-07-31 Beckman Coulter, Inc. Detecting phosphorylated tau (p-tau) 217 using chemiluminescent dioxetane compounds
CN119334929B (zh) * 2024-11-19 2026-02-24 中元汇吉生物技术股份有限公司 一种提升磷酸化tau蛋白检测灵敏度的方法及其试剂盒

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
CN100572392C (zh) 2002-07-12 2009-12-23 阿克松神经科学研究和发展股份有限公司 截短tau蛋白
CN101284136A (zh) 2002-12-03 2008-10-15 布朗歇特洛克菲勒神经科学研究所 传输物质穿过血脑屏障的人工低密度脂蛋白载体
EP1585520A1 (en) 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) * 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
JP5599454B2 (ja) * 2009-08-06 2014-10-01 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
ES2656442T3 (es) * 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
US9371376B2 (en) * 2011-12-20 2016-06-21 Janssen Biotech, Inc. Anti-PHF-tau antibodies and their uses
US8853505B2 (en) * 2012-02-27 2014-10-07 Syngenta Participations Ag Variety corn line AA2205
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
SI3221349T1 (sl) * 2014-11-19 2021-02-26 Axon Neuroscience Se Humanizirano tau protitelo pri alzheimerjevi bolezni
EP3412688A4 (en) * 2016-02-05 2019-12-04 Jiangsu Hengrui Medicine Co., Ltd. THROMBIN ANTIBODY, ANTIGENBINDING FRAGMENT, AND PHARMACEUTICAL USE THEREOF

Similar Documents

Publication Publication Date Title
JP2021520777A5 (https=)
RU2020135052A (ru) Способы выявления и лечения болезни альцгеймера на основе антител
JP7837375B2 (ja) ピログルタメートアミロイド－βに対する抗体及びその使用
JPWO2019186276A5 (https=)
JP7399096B2 (ja) 神経変性を検出するためのアッセイ
CA2806076A1 (en) Anti-tumor antigen antibodies and methods of use
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78
CN116348769A (zh) 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定
JP2023052165A (ja) Ｈ１．０ｋ１８０ｍｅ２抗体、その作製および使用の方法
CN110461874B (zh) 抗gitr抗体、其抗原结合片段及其医药用途
US20230034474A1 (en) Novel Molecules for Diagnosis
US11009507B2 (en) Methods and diagnostics for cancer detection and treatment monitoring
KR101098186B1 (ko) 피에이유에프(ｐａｕｆ) 특이적인 인간 단일클론항체, 이를 포함하는 암 치료용 조성물, 이를 이용하는 암의 진단방법
IL323614A (en) Detection of autoantibodies against nr1
CN113527484B (zh) 抗cd47单克隆抗体
CN116375874A (zh) 一种cd33抗体及其应用
CN117178189A (zh) 用于检测血浆和脑脊液中的神经丝轻链的方法
WO2021175191A1 (zh) 抗tim-3抗体及其用途
KR102757524B1 (ko) Cd47에 특이적인 인간화 항체 및 이를 포함하는 cd47 관련 질환의 예방 또는 치료용 약학적 조성물
CN115124620B (zh) 一种能够激活nk细胞的抗体及其应用
TW201915016A (zh) 單株抗體或其抗原結合片段及其用途
WO2025037271A1 (en) Plasma assay for detecting cns-derived tau peptides
WO2026073156A1 (en) Detection of autoantibodies against nr1
CN121464158A (zh) 抗Claudin18.2抗体及其制备和使用方法
CN121152803A (zh) Ceacam6结合抗体和其抗原结合片段